The Bioshares Top 10 Picks for 2011
Abstract: Starpharma is carving up and carving out in as many ways as possible product and application opportunities from its dendrimer chemistry platform. Dendrimers are synthetic, branch like chemical structures that can be engineered very precisely. The addition of smaller functional groups on the periphery or even with the greater structure is what makes the chemistry so versatile.
Download: Bioshares Issue 392 ( pdf file, 45kb)
Results of Annual General Meeting 2010
In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act, we advise that details of the resolutions and the proxies received in respect of each resolution considered by the Starpharma Holdings Limited Annual General Meeting are set out in the attached proxy summary.
AGM 2010 Chairman's Address & CEO Presentation
View the Chairman's address and CEO's presentations from the 2010 Annual General Meeting held on 11 November 2010.
AGM 2010 Chairman & CEO's Presentation ( pdf file, 1012kb)
Starpharma's Partner SSL acquired by Reckitt Benckiser
Reckitt Benckiser has announced that it has completed its £2.5bn acquisition of SSL after gaining approval from more than 85% of SSL's shareholders by last Friday. As a result, SSL is now formally part of Reckitt Benckiser and its leading global condom brand Durex will be added to Reckitt’s portfolio of health and personal care “Powerbrands” which include Nurofen, Strepsils and Clearasil.
Quarterly Cashflow Report - September 2010
The cash balance at 30 September 2010 was $20.2m. The Operating & Investing cash outflow of $2.4m for the quarter includes the set-up and upfront costs of the phase 2 bacterial vaginosis study for VivaGel® commenced in July.
Starpharma presents at ASX Small to Mid Caps conference, Hong Kong
Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is one of 20 Australian companies, and one of only two Biotechs, selected to present at the third annual ASX Small to Mid Caps conference in Hong Kong. The ASX Hong Kong conference is part of a series of international investor events designed to showcase emerging Australian small and mid-cap listed companies to investors in Asia, Europe and the US.
Starpharma Expands Lilly Partnership
Starpharma today announced the signing of a collaborative research agreement with leading US pharmaceutical corporation Eli Lilly and Company.
The new agreement relates to a co-development program for one of Starpharma’s dendrimer-drug conjugates.
Starpharma annual report and full year financial results
Starpharma today released its annual report and financial results for the year ended 30 June 2010.
Cash reserves of $22.8 million are a result of prudent management of cash, successful capital raising and continuing partnering revenues, and interest received throughout the year.
The 6th Bioshares 2010 Biotech Summit
Abstract: While much has been communicated about Starpharma's Vivagel product and its application as a microbicidal condom coating, the company was asked to present on the rapidly strengthening interest in the use of the company's dendrimers for the application of drug delivery.
Download: Bioshares Issue 369 ( pdf file, 26kb)